Navigation Links
NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease
Date:11/20/2012

NESS ZIONA, Israel, November 20, 2012 /PRNewswire/ --

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

In pre-clinical studies of ND0612, plasma concentrations of levodopa reached straight-line steady state levels. The current Phase I double-blind, dose-escalation trial in young, healthy volunteers will assess ND0612 for safety and tolerability as well as for levodopa and carbidopa steady state plasma levels.

"This first trial of ND0612 in man is a significant step in the development of a new levodopa treatment standard for Parkinson's disease," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "For many years, oral levodopa has been the leading Parkinson's disease drug therapy. However, due to low and erratic oral levodopa bioavailability, advanced Parkinson's patients suffer from debilitating motor complications even under the best current standard of care. Should ND0612 achieve constant levodopa base blood levels, than low, harmful levodopa trough levels would be prevented, the efficacy of current levodopa therapy could be significantly raised and a new standard of care in our ability to treat and reduce motor complications in Parkinson's disease patients may be established."

About Parkinson's Disease

Parkinson's disease affects approximately 6M patients in the world. It is caused by decreasing dopamine signaling in the brain as dopaminergic brain cells die off. Levodopa is the "Gold Standard" therapy for Parkinson's disease and virtually all patients receive it. When administered thro
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... -- Hovione today announced that its API plant ... a pre-approval inspection by the US Food and Drug Administration ... Consumer Safety Officer, Ms. Britanny Terhar , lasted 5 ... and concluded on the 25 th . The inspection confirmed ... of Good Manufacturing Practices (GMP) and no Form 483 observations ...
(Date:7/31/2014)... NEW YORK and VIENNA , ... today at a press conference in New York ... of PD01A, a vaccine against Parkinson,s disease. PD01A is the ... target, to enter clinical testing. The Michael J. ... a $ 1.5 million grant, and presented at the press ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... April 21, 2011 iMD Companies (ICBU.PK) is pleased ... Testing Facility (IDTF), Optimum Mobile Imaging LLC, which increases ...  The acquisition was done with cash and restricted stock ... can be found at www.OMIAZ.com .   OMI ...
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, ... today the Company,s attendance at the upcoming International Society ... 26 – 29, 2011.  The meeting will be held ... / Palazzo Hotels in Las Vegas, Nevada.   ...
Cached Medicine Technology:iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 2iMD Companies, Inc. Acquires OMI LLC and Files Financials for 2010 3MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting 2
(Date:7/31/2014)... 31, 2014 Leelanau Peninsula’s newest winery, ... 2014 at 7788 East Horn Road in Lake Leelanau. Joining ... , Aurora Cellars is the 25th winery along the trail. ... popular wine tour events, making its trail event debut during ... , Owners David and Faye Mathia opened the boutique ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now offering a ... Systematic Review of Sexual Satisfaction . The course ... of Clinical and Health Psychology. , This CE course ... have accurate information about sexual satisfaction so that healthcare ... material provides a systematic review of 197 research publications ...
(Date:7/31/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... Dayton, Ohio (PRWEB) July 31, 2014 ... members of its faculty, Anthony Le Donne and Peter ... 1. Also new to United is a Director ... on August 1. , Anthony Le Donne, Assistant ... University, United Kingdom. He teaches New Testament, Second Temple ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2
... Upheld Against Mesothelioma Victim,s Former Employers, BATON ... after,winning a $3.2 million verdict against contractors Parsons ... on behalf of,mesothelioma victim Ray Rando, Baron & ... by the Louisiana First Circuit Court of Appeal.,Rando, ...
... studies in 15 Finnish families have shown that ... aptitude. Musical aptitude was determined using three tests: ... test), and the Seashore pitch and time discrimination ... genetic study that aims in the identification of ...
... (NEWARK, N.J., May 19, 2008) The New Jersey Department ... Governors Nursing Merit Award for excellence in the nurse researcher: ... faculty member, during a dinner at the Hyatt Regency Hotel, ... College of Nursing at Rutgers, The State University of New ...
... May 18, 2008 New study results indicated ... lead to significant relief of overall symptoms of Irritable ... presented at Digestive Disease Week (DDW) 2008, the largest ... , IBS-C is a multi-symptom disorder and is one ...
... The following is being,issued by AIDS Action:, ... Epidemic at Home: The Need for a National AIDS,Strategy", ... (Lunch provided at 12:45 p.m.), WHERE: Rayburn Building, ... Baldwin (D-WI), Representative Donna Christensen (D-VI), Representative ...
... Wi-Fi-Based Location Tracking Application to More than 50 ... ... Ekahau Inc., a leading,provider of Wi-Fi-based Real Time Location Systems (RTLS), ... organization in that country to use Ekahau RTLS to ensure the,safety of ...
Cached Medicine News:Health News:Asbestos Verdict Upheld by Louisiana Court of Appeal, Announces Baron & Budd 2Health News:Rutgers College of Nursing's Linda Flynn to receive N.J. Governor's Nursing Merit Award 2Health News:New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women 2Health News:Tuesday Congressional Briefing Relays Need for National AIDS Strategy 2Health News:Tuesday Congressional Briefing Relays Need for National AIDS Strategy 3Health News:GGZ-NML Hospital Deploys Ekahau RTLS for Staff Safety in Psychiatric Care Unit 2
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: